Endo Pharma in withdrawal: FDA requests opioid drug’s removal from the market
Endo Pharma | June 09, 2017
In a first for the U.S. Food and Drug Administration, the regulator has requested Endo Pharmaceuticals to remove its reformulated Opana ER (oxymorphone hydrochloride) opioid drug from the market. The move follows an FDA advisory committee vote of 18-8 in March concluding the drug’s risks were greater than the benefits.